Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue 6, 1999, Pages 896-901

  Keks, Nicholas A ^a   Altson, Kylie ^a   Hope, Judy ^a   Krapivensky, Natalie ^a   Culhane, Christine ^a   Tanaghow, Amgad ^a   Doherty, Peter ^a   Bootle, Anne ^a  

^a Psychiatric Service   (Australia)

Author keywords

Antipsychosis; Community treatment; Mood stabilisers; Psychosis; Schizophrenia

Indexed keywords

AMITRIPTYLINE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUOXETINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PRIMOZIDE; PROCYCLIDINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VALPROIC ACID; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; DEPRESSION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; URBAN POPULATION;

EID: 0033385155     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.1999.00639.x     Document Type: Article

References (16)

1. Keks NA, Kulkarni J, Copolov DL. Treatment of schizophrenia. The Medical Journal of Australia 1989; 151:467.
2. Kane JM, McGlashan TH. Treatment of schizophrenia. The Lancet 1995; 345:25.
3. Kane J, Honigfeld G, Singer J, Meltzer H. The Clozaril Collaborative Study Group. Clozapine for the treatment of the resistant schizophrenic: a double blind comparison vs. chlorpromazine/benztropine. Archives of General Psychiatry 1988; 45:789-796.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994; 151:825-835.
5. Marder SR, Davis JM, Chouinard G. The effects of Risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry 1997; 58:538-546.
6. Tollefson GD, Beasley CM, Tran PV et al. Olanzapine vs. haloperidol in the treatment of schizophrenia and schizo-affective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997; 154:457-465.
7. Tollefson GD, Sanger TM. Negative symptoms: a path analytical approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry 1997; 154:466-474.
8. Parker G, Lambert T, McGrath J, McGorry P, Tiller J. Neuroleptic management of schizophrenia: a survey and commentary on Australian psychiatric practice. Australian and New Zealand Journal of Psychiatry 1998; 32:50-58.
9. Galletly C. Prescribing of psychotropic drugs in an acute inpatient unit. Australian and New Zealand Journal of Psychiatry 1999; 33:281-282.
10. Diagnostic and statistical manual of mental disorders. 4th ed, Washington, DC: American Psychiatric Association, 1994.
11. Smith RC, Strizich M, Klass D. Drug history and tardive dyskinesia. American Journal of Psychiatry 1978; 135:1402-1403.
12. Kane JM, Lieberman JA. Adverse effects of psychotropic drugs. New York: Guilford, 1992.
13. Luchins DJ, Klass D, Hanrahan P, Malan R, Harris J. Alteration in the recommended dosing schedule for risperidone. American Journal of Psychiatry 1998; 155:365-366.
14. Keks N. Schizophrenia. Australian Journal of Hospital Pharmacy 1996; 26:93-96.
15. Johnstone EC, Crow TJ, Frith CD, Owens DG. The Northwick Park 'functional' psychosis study: diagnosis and treatment response. Lancet 1988; 2:119-126.
16. American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. American Journal of Psychiatry 1997; 154; (Suppl.)